Search Results - "Linn, SC"

Correction: A scoping review of statistical methods in studies of biomarker-related treatment heterogeneity for breast cancer by Sollfrank, L, Linn, SC, Hauptmann, M, Jóźwiak, K

Get full text

A scoping review of statistical methods in studies of biomarker-related treatment heterogeneity for breast cancer by Sollfrank, L, Linn, S C, Hauptmann, M, Jóźwiak, K

“…Many scientific papers are published each year and substantial resources are spent to develop biomarker-based tests for precision oncology. However, only a…”
Get full text

Abstract PD4-12: Clustering of activated proteins of the PI3K and MAPK pathways distinguishes ER+/HER2- primary breast cancer patients with preferential tamoxifen benefit by Kruger, DT, Beelen, K, Opdam, M, Sanders, J, van der Noort, V, Boven, E, Linn, SC

“…Abstract Background Several (activated) proteins of the phosphatidylinositol-3-kinase (PI3K) and/or mitogen-activated protein kinase (MAPK) pathway have been…”
Get full text

Characterization of HER2‐low breast cancer in young women with germline BRCA1/2 pathogenetic variants: Results of a large international retrospective cohort study by Schettini, Francesco, Blondeaux, Eva, Molinelli, Chiara, Bas, Raphaëlle, Kim, Hee Jeong, Di Meglio, Antonio, Bernstein Molho, Rinat, Linn, Sabine C., Pogoda, Katarzyna, Carrasco, Estela, Punie, Kevin, Agostinetto, Elisa, Lopetegui‐Lia, Nerea, Phillips, Kelly‐Anne, Toss, Angela, Rousset‐Jablonski, Christine, Acheritogaray, Marion, Ferrari, Alberta, Paluch‐Shimon, Shani, Fruscio, Robert, Cui, Wanda, Wong, Stephanie M., Vernieri, Claudio, Dieci, Maria Vittoria, Matikas, Alexios, Rozenblit, Mariya, Villarreal‐Garza, Cynthia, De Marchis, Laura, Puglisi, Fabio, Vasconcelos de Matos, Leonor, Mariño, Monica, Teixeira, Luis, Graffeo, Rossella, Rognone, Alessia, Chirco, Alessandra, Antone, Nicoleta, Abdou, Yara, Marhold, Maximilian, Božović‐Spasojević, Ivana, Cortés Salgado, Alfonso, Carmisciano, Luca, Bruzzone, Marco, Curigliano, Giuseppe, Prat, Aleix, Lambertini, Matteo

“…Background Breast cancer (BC) in women aged ≤40 years carrying germline pathogenetic variants (PVs) in BRCA1/2 genes is infrequent but often associated with…”
Get full text

Abstract P1-13-10: Adjuvant treatment of HER2+ breast cancer: Should trastuzumab be given sequentially or concurrently with chemotherapy? by Dackus, GMHE, Jóźwiak, K, Van der Wall, E, Van Diest, PJ, Hauptmann, M, Siesling, S, Sonke, GS, Linn, SC

“…Abstract Background Human Epidermal growth factor Receptor 2 positive (HER2+) breast cancers have a high risk of recurrence in the absence of systemic…”
Get full text

Abstract P4-08-06: Phosphorylation of insulin-like growth factor-1 receptor (IGF-1R) is associated with tamoxifen resistance by activating the PI3K/MAPK pathway by Kruger, DT, Alexi, X, Opdam, M, Schuurman, KG, Sanders, J, van der Noort, V, Boven, E, Zwart, W, Linn, SC

“…Abstract Background IGF-1R is overexpressed in a substantial number of breast cancer cases. When phosphorylated, IGF-1R activates the PI3K and MAPK pathways…”
Get full text

Induction of small cell lung cancer by somatic inactivation of both Trp53 and Rb1 in a conditional mouse model by Meuwissen, Ralph, Linn, Sabine C, Linnoila, R.Ilona, Zevenhoven, John, Mooi, Wolter J, Berns, Anton

“…Small cell lung cancer (SCLC) is a highly aggressive human tumor with a more than 95% mortality rate. Its ontogeny and molecular pathogenesis remains poorly…”
Get full text

Abstract P2-09-16: How population-based data complement trial data in the adjuvant endocrine treatment of ER+/HER2+ breast cancers by Dackus, GMHE, Jozwiak, K, Sonke, GS, Van der Wall, E, Van Diest, PJ, Hauptmann, M, Siesling, S, Linn, SC

“…Abstract Background This study is part of the Netherlands Breast Cancer Project, initiated to address research questions that are unlikely answered by future…”
Get full text

Abstract OT1-01-08: Intensified alkylating chemotherapy in patients with oligo-metastatic breast cancer harboring homologous recombination deficiency: The OLIGO study by Steenbruggen, TG, Vrancken Peeters, M-JTFD, Scholten, AN, Schot, M, Wesseling, J, Linn, SC, Sonke, GS

“…Abstract Background Approximately 5% of patients with metastatic breast cancer survive more than 10 years. Long-term survival is mostly seen in patients with…”
Get full text

Abstract P4-21-30: Long-term survival in HER2-positive metastatic breast cancer: The first blow is half the battle by Steenbruggen, TG, van Ramshorst, MS, Stouthard, JML, Rodenhuis, S, Linn, SC, Sonke, GS, Smorenburg, CH

“…Abstract Introduction: Metastatic breast cancer (MBC) is considered an incurable disease. However, long-term survival is increasingly observed in HER2-positive…”
Get full text

Optimal adjuvant endocrine treatment of ER+/HER2+ breast cancer patients by age at diagnosis: A population-based cohort study by Dackus, G.M.H.E., Jóźwiak, K., Sonke, G.S., van der Wall, E., van Diest, P.J., Hauptmann, M., Siesling, S., Linn, S.C.

“…Prior randomised controlled trials on adjuvant hormonal therapy included HER2any patients; however, a differential effect of aromatase inhibitors (AIs) versus…”
Get full text

Abstract P1-06-07: Characterization of chromosomal instability in the TNT trial: A randomized phase III trial of carboplatin compared with docetaxel for patients with metastatic or recurrent locally advanced triple negative or BRCA1/2 breast cancer (CRUK/07/012) by Sipos, O, Tovey, H, Quist, J, Haider, S, Nowinski, S, Gazinska, P, Kernaghan, S, Toms, C, Timms, KM, Lanchbury, JS, Linn, SC, Pinder, SE, Bliss, JM, Tutt, A, Cheang, MC, Grigoriadis, A

“…Abstract Background A distinctive trait of triple negative breast cancer (TNBC) is the acquisition of genome wide highly aberrant copy number states, which is…”
Get full text

Adjuvant dose-dense doxorubicin-cyclophosphamide versus docetaxel-doxorubicin-cyclophosphamide for high-risk breast cancer: First results of the randomised MATADOR trial (BOOG 2004-04) by van Rossum, A.G.J., Kok, M., van Werkhoven, E., Opdam, M., Mandjes, I.A.M., van Leeuwen – Stok, A.E., van Tinteren, H., Imholz, A.L.T., Portielje, J.E.A., Bos, M.M.E.M., van Bochove, A., Wesseling, J., Rutgers, E.J., Linn, S.C., Oosterkamp, H.M.

“…Dose-dense administration of chemotherapy and the addition of taxanes to anthracycline-based adjuvant chemotherapy have improved breast cancer survival…”
Get full text

Abstract PD5-02: The effect of trastuzumab-based therapy on overall survival in small, node-negative HER2-positive breast cancer: To treat or not to treat? by van Ramshorst, MS, van der Heijden-van der Loo, M, Dackus, GMHE, Linn, SC, Sonke, GS

“…Abstract Background Since the addition of trastuzumab to (neo)adjuvant chemotherapy, the prognosis of patients with stage II and III HER2-positive breast…”
Get full text

Abstract OT1-03-10: A phase I followed by a r andomiz e d phase II trial of two cycles carboplatin-olaparib followed by olaparib monotherapy v ersus capec i tabine in BRCA-1 or -2 mutated Her2 negative ad v anced breast c a ncer as first l ine treatment (REVIVAL study) by Dackus, GMHE, Schouten, PC, Geenen, JJ, Marchetti, S, Sonke, GS, Linn, SC, Schellens, JHM

“…Abstract Background Preclinical studies revealed that the combination of platinum compounds and olaparib is additive and possibly even synergistic in cell…”
Get full text

Abstract S6-06: The effect of trastuzumab-based therapy on overall survival in small, node-negative HER2-positive breast cancer: To treat or not to treat? by van Ramshorst, MS, van der Heijden-van der Loo, M, Dackus, GMHE, Linn, SC, Sonke, GS

“…Abstract Background Since the addition of trastuzumab to (neo)adjuvant chemotherapy, the prognosis of patients with stage II and III HER2-positive breast…”
Get full text

Abstract P4-14-11: No impact of osteoporosis or bisphosphonate use for osteoporosis on breast cancer outcome: A sub-study of the DATA trial by van Hellemond, IE, Smorenburg, CH, Peer, PG, Swinkels, AC, Seynaeve, CM, van der Sangen, MJ, Kroep, JR, de Graaf, H, Honkoop, AH, Erdkamp, FL, van den Berkmortel, FW, de Roos, WK, Linn, SC, Imholz, AL, de Boer, M, Tjan-Heijnen, VC

“…Abstract Background: The phase III DATA study (NCT00301457) investigates the efficacy of 6 versus 3 years of adjuvant anastrozole after an initial 2-3 year…”
Get full text

Abstract OT2-07-08: Substantially improving the cure rate of high-risk BRCA1-like breast cancer patients with personalized therapy (SUBITO) - an international randomized phase III trial by Vliek, S, Jager, A, Jonge-Lavrencic, M, Lotz, J-P, Gonçalves, A, Graeser, M, Nitz, U, Mandjes, IAM, Holtkamp, MJ, Schot, M, Retel, VP, Kuip, EJ, Wymenga, MN, Konings, IR, Tjan-Heijnen, VCG, Kroep, JR, Schroeder, CP, Van der Wall, E, Linn, SC

“…Abstract Background: An intact homologous repair (HR) pathway is essential for error-free repair of DNA double strand breaks (DSB). Preclinical and clinical…”
Get full text

Molecular characterisation of soft tissue tumours: a gene expression study by Nielsen, Torsten O, West, Rob B, Linn, Sabine C, Alter, Orly, Knowling, Margaret A, O'Connell, John X, Zhu, Shirley, Fero, Mike, Sherlock, Gavin, Pollack, Jonathan R, Brown, Patrick O, Botstein, David, van de Rijn, Matt

“…Soft-tissue tumours are derived from mesenchymal cells such as fibroblasts, muscle cells, or adipocytes, but for many such tumours the histogenesis is…”
Get full text

Abstract P3-07-28: BRCA1-like profile as predictive biomarker in non myeloablative chemotherapy (GAIN study) by van Rossum, AGJ, Schouten, PC, Weber, KE, Nekljudova, V, Denkert, C, von Minckwitz, G, Karn, T, Möbus, VJ, Linn, SC, Loibl, S, Marmé, F

“…Abstract Background: The BRCA1-like copy number (CN) profile can be used as a biomarker to predict which stage III breast cancer patients benefit from…”
Get full text